A Meta Analysis Of Concurrent Versus Sequential Chemoradiotherapy For Limited Stage Small Cell Lung Cancer

Lung cancer is one of the most common worldwide malignancies. Themorbidity and mortality of LC is ranking the first in a variety of malignanttumors, the mortality of it is up to92%.12.95%of LC are small cell lungcancer, which limited stage small cell lung cancer (LS-SCLC) accounts for27%of SCLC.Objevtive：To evaluate the efficacy and adverse reactions of concurrent versussequential chemoradiotherapy.Method:Searching randomized controlled trials about concurrent versussequential chemoradiotherapy for limited stage small cell lung cancer,which is publishedfrom2004to2014. Using the Cochrane CollaborationRevman5.0Meta-analysis to study.Result:Small cell lung cancer: we searched seven randomized controlled trials,including a total of1010cases of limited stage small cell lung cancer patients,study quality assessment were four RCTs have moderate risk of bias, as ClassB;3RCTs with high degree of bias risk, as the C-Class. Meta-analysis showed that, for LS-SCLC concurrent chemoradiotherapy is higher in CR+PR, withstatistical significance [RR=1.06,95%CI (1.02,1.10), P=0.005].1-yearsurvival rate, with statistical significance [RR=1.13,95%CI (1.01,1.26), P=0.03](Figure4-2).2-year survival rate, with statistical significance [RR=1.38,95%CI (1.17,1.63), P=0.0001].3-year survival improved with statisticalsignificance [RR=1.27,95%CI (1.00,1.60), P=0.05].5-year survival rate,with statistical significance [RR=1.46,95%CI (1.04,2.06), P=0.03]. Toxicityaspects: III/IV neutropenia incidence increased with statistical significance[RR=1.23,95%CI (1.14,1.32), P <0.00001=(Figure4-6). III/IVthrombocytopenia increased incidence, with statistical significance [RR=1.44,95%CI (1.15,1.81), P=0.001] III/IV anemia, III/IV esophagitis,pneumonia, III/IV degree of nausea and vomiting incidence difference was notstatistically significant.Conclusion1. concurrent chemoradiotherapy is higher than sequential chemoradioth-erapy at the efficiency2. concurrent chemoradiotherapy program have a higher rate of III/IVneutropenia and III/IV thrombocytopenia incidence;...